New pill shows promise against tough lung cancer in early trial
NCT ID NCT04258033
First seen Jun 09, 2026 · Last updated Jun 14, 2026 · Updated 1 time
Summary
This study tested an oral drug called PLB1001 in 145 people with advanced non-small cell lung cancer whose tumors have a specific genetic change (c-Met dysregulation). The main goal was to see how many patients' tumors shrank or disappeared. The drug is taken twice daily and aims to control the disease, not cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Guangdong General Hospital
Guangzhou, Guangdong, 510080, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.